Aclaris Therapeutics (ACRS) Reports A-101 45% Topical Solution Meets Primary/Secondary Efficacy Endpoints in 2nd Ph.3 Clinical Trial for Treament of THWART-1
Go back to Aclaris Therapeutics (ACRS) Reports A-101 45% Topical Solution Meets Primary/Secondary Efficacy Endpoints in 2nd Ph.3 Clinical Trial for Treament of THWART-1| (NASDAQ: ACRS) | Delayed: 4.84 +0.34 (7.56%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.50 | 52 Week High | $33.88 | |||
| Open | $4.55 | 52 Week Low | $14.12 | |||
| Day High | $4.93 | P/E | N/A | |||
| Day Low | $4.50 | EPS | $0.00 | |||
| Volume | 1,819,281 | |||||
